EGFR and adenocarcinoma: EGFR and KRAS G12C mutations were found almost exclusively in adenocarcinoma (7.8% and 13.3%, respectively), with very low prevalence in squamous carcinomas or NOS/other categories/not classified (p < 0.001 for both).